Literature DB >> 22573634

COMT Val158Met genotype influences neurodegeneration within dopamine-innervated brain structures.

E D Gennatas1, J A Cholfin, J Zhou, R K Crawford, D A Sasaki, A Karydas, A L Boxer, S J Bonasera, K P Rankin, M L Gorno-Tempini, H J Rosen, J H Kramer, M Weiner, B L Miller, W W Seeley.   

Abstract

OBJECTIVE: We sought to determine whether the Val(158)Met polymorphism in the catechol-O-methyltransferase (COMT) gene influences neurodegeneration within dopamine-innervated brain regions.
METHODS: A total of 252 subjects, including healthy controls and patients with Alzheimer disease, behavioral variant frontotemporal dementia, and semantic dementia, underwent COMT genotyping and structural MRI.
RESULTS: Whole-brain voxel-wise regression analyses revealed that COMT Val(158)Met Val allele dosage, known to produce a dose-dependent decrease in synaptic dopamine (DA) availability, correlated with decreased gray matter in the region of the ventral tegmental area (VTA), ventromedial prefrontal cortex, bilateral dorsal midinsula, left dorsolateral prefrontal cortex, and right ventral striatum. Unexpectedly, patients carrying a Met allele showed greater VTA volumes than age-matched controls. Gray matter intensities within COMT-related brain regions correlated with cognitive and behavioral deficits.
CONCLUSIONS: The results are consistent with the hypothesis that increased synaptic DA catabolism promotes neurodegeneration within DA-innervated brain regions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22573634      PMCID: PMC3359506          DOI: 10.1212/WNL.0b013e3182574fa1

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

Review 1.  The basal ganglia: anatomy, physiology, and pharmacology.

Authors:  Stephen Tisch; Paul Silberstein; Patricia Limousin-Dowsey; Marjan Jahanshahi
Journal:  Psychiatr Clin North Am       Date:  2004-12

Review 2.  Brain imaging, genetics and emotion.

Authors:  André Aleman; Marte Swart; Sophie van Rijn
Journal:  Biol Psychol       Date:  2008-02-02       Impact factor: 3.251

3.  Patterns of brain atrophy in frontotemporal dementia and semantic dementia.

Authors:  H J Rosen; M L Gorno-Tempini; W P Goldman; R J Perry; N Schuff; M Weiner; R Feiwell; J H Kramer; B L Miller
Journal:  Neurology       Date:  2002-01-22       Impact factor: 9.910

Review 4.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

Authors:  D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

Review 5.  The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Authors:  J L Cummings
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

6.  Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype.

Authors:  Andreas Meyer-Lindenberg; Philip D Kohn; Bhaskar Kolachana; Shane Kippenhan; Aideen McInerney-Leo; Robert Nussbaum; Daniel R Weinberger; Karen Faith Berman
Journal:  Nat Neurosci       Date:  2005-04-10       Impact factor: 24.884

7.  Catechol-O-methyltransferase gene polymorphism is associated with risk of psychosis in Alzheimer Disease.

Authors:  Barbara Borroni; Chiara Agosti; Silvana Archetti; Chiara Costanzi; Silvia Bonomi; Diego Ghianda; Gian Luigi Lenzi; Luigi Caimi; Monica Di Luca; Alessandro Padovani
Journal:  Neurosci Lett       Date:  2004-11-11       Impact factor: 3.046

8.  Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function.

Authors:  M Matsumoto; C Shannon Weickert; M Akil; B K Lipska; T M Hyde; M M Herman; J E Kleinman; D R Weinberger
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

9.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

10.  Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain.

Authors:  Jingshan Chen; Barbara K Lipska; Nader Halim; Quang D Ma; Mitsuyuki Matsumoto; Samer Melhem; Bhaskar S Kolachana; Thomas M Hyde; Mary M Herman; Jose Apud; Michael F Egan; Joel E Kleinman; Daniel R Weinberger
Journal:  Am J Hum Genet       Date:  2004-09-27       Impact factor: 11.025

View more
  13 in total

1.  Satiety-related hormonal dysregulation in behavioral variant frontotemporal dementia.

Authors:  Josh D Woolley; Baber K Khan; Alamelu Natesan; Anna Karydas; Mary Dallman; Peter Havel; Bruce L Miller; Katherine P Rankin
Journal:  Neurology       Date:  2014-01-10       Impact factor: 9.910

Review 2.  Diagnosis and management of behavioral issues in frontotemporal dementia.

Authors:  Masood Manoochehri; Edward D Huey
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

3.  COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users.

Authors:  Antonio Verdejo-García; Ana Beatriz Fagundo; Aida Cuenca; Joan Rodriguez; Elisabet Cuyás; Klaus Langohr; Susana de Sola Llopis; Ester Civit; Magí Farré; Jordi Peña-Casanova; Rafael de la Torre
Journal:  Neuropsychopharmacology       Date:  2013-02-28       Impact factor: 7.853

4.  Common genetic variation is associated with longitudinal decline and network features in behavioral variant frontotemporal degeneration.

Authors:  Lauren Massimo; Lior Rennert; Sharon X Xie; Christopher Olm; Jessica Bove; Vivianna Van Deerlin; David J Irwin; Murray Grossman; Corey T McMillan
Journal:  Neurobiol Aging       Date:  2021-08-03       Impact factor: 4.673

5.  Decision tree analysis of genetic risk for clinically heterogeneous Alzheimer's disease.

Authors:  Jennifer S Yokoyama; Luke W Bonham; Renee L Sears; Eric Klein; Anna Karydas; Joel H Kramer; Bruce L Miller; Giovanni Coppola
Journal:  BMC Neurol       Date:  2015-03-28       Impact factor: 2.474

6.  VNTR-DAT1 and COMTVal158Met Genotypes Modulate Mental Flexibility and Adaptive Behavior Skills in Down Syndrome.

Authors:  Laura Del Hoyo; Laura Xicota; Klaus Langohr; Gonzalo Sánchez-Benavides; Susana de Sola; Aida Cuenca-Royo; Joan Rodriguez; Jose Rodríguez-Morató; Magí Farré; Mara Dierssen; Rafael de la Torre
Journal:  Front Behav Neurosci       Date:  2016-10-17       Impact factor: 3.558

7.  Effect of Functional BDNF and COMT Polymorphisms on Symptoms and Regional Brain Volume in Frontotemporal Dementia and Corticobasal Syndrome.

Authors:  Edward D Huey; Rachel Fremont; Masood Manoochehri; Yunglin Gazes; Seonjoo Lee; Stephanie Cosentino; Michael Tierney; Eric M Wassermann; Parastoo Momeni; Jordan Grafman
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2020-05-13       Impact factor: 2.198

8.  Meta-analyses of 8 polymorphisms associated with the risk of the Alzheimer's disease.

Authors:  Xuting Xu; Yunliang Wang; Lingyan Wang; Qi Liao; Lan Chang; Leiting Xu; Yi Huang; Huadan Ye; Limin Xu; Cheng Chen; Xiaowei Shen; Fuqiang Zhang; Meng Ye; Qinwen Wang; Shiwei Duan
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

9.  Catechol-O-methyltransferase Val158Met polymorphism modulates gray matter volume and functional connectivity of the default mode network.

Authors:  Tian Tian; Wen Qin; Bing Liu; Dawei Wang; Junping Wang; Tianzi Jiang; Chunshui Yu
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

10.  COMT Val158Met Polymorphism Modulates Huntington's Disease Progression.

Authors:  Ruth de Diego-Balaguer; Catherine Schramm; Isabelle Rebeix; Emmanuel Dupoux; Alexandra Durr; Alexis Brice; Perrine Charles; Laurent Cleret de Langavant; Katia Youssov; Christophe Verny; Vincent Damotte; Jean-Philippe Azulay; Cyril Goizet; Clémence Simonin; Christine Tranchant; Patrick Maison; Amandine Rialland; David Schmitz; Charlotte Jacquemot; Bertrand Fontaine; Anne-Catherine Bachoud-Lévi
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.